Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount 
DeepSeek Targets $7.4 Billion Funding Round, Valuation Could Reach $59 Billion in 2026 
Alphabet Unveils $80 Billion Capital Raise to Accelerate AI Expansion, Secures $10 Billion Backing from Berkshire Hathaway 
Palo Alto Networks Q3 FY2026 Earnings Surge on Strong AI Security Demand, Raises Full-Year Outlook 
Anthropic Files for IPO, Signaling a New Era for Public AI Investments in 2026 
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand 
TSMC Sees Strong AI-Driven Growth as Demand for Advanced Chips Continues to Surge 
Lynas Rare Earths Names Pol Le Roux as Interim CEO Ahead of Leadership Change 
Treasury Wine Estates to Focus on Penfolds and Key Brands in Major Cost-Cutting Overhaul 
Atlas Renewable Energy Freezes $1 Billion Brazil Investment Amid Renewable Energy Curtailment 
SpaceX Sets IPO Price at $135 Per Share Ahead of Historic Nasdaq Debut 
HPE Raises 2026 Outlook After Record Q2 Revenue Fueled by AI Server Demand 
SpaceX Targets Record-Breaking $75 Billion IPO at $135 Per Share in Historic Market Debut 
Syria Airspace Sees Sharp Rise in Flights as Airlines Reroute Around Middle East Conflict 
US Expands Iran Sanctions, Targets Major Crypto Exchanges and Individuals 
Jensen Huang Strengthens Nvidia’s South Korea Ties Amid AI Expansion 
Morgan Stanley Upgrades Winbond and Nanya to Overweight on Strong Memory Chip Market Outlook 
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
